礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LLY 礼来

休市中 04-17 16:00:00 EDT

839.96

+105.06

+14.30%

盘后844.00

+4.04+0.48%

19:59 EDT

最高858.00	最低821.84	成交量1,085万
今开840.80	昨收734.90	日振幅4.92%
总市值7,963亿	流通市值7,946亿	总股本9.48亿
成交额91.52亿	换手率1.15%	流通股本9.46亿
市净率56.11	ROE84.26%	每股收益11.71
52周最高972.53	52周最低677.09	市盈率71.73
股息5.20	股息收益率0.01	ROA15.33%

北京优虎网络科技有限公司

{"stockData":{"symbol":"LLY","market":"US","secType":"STK","nameCN":"礼来","latestPrice":839.96,"timestamp":1744920000000,"preClose":734.9,"halted":0,"volume":10853283,"hourTrading":{"tag":"盘后","latestPrice":844,"preClose":839.96,"latestTime":"19:59 EDT","volume":140169,"amount":117746598.8407,"timestamp":1744934397934},"delay":0,"floatShares":946000000,"shares":947989151,"eps":11.71,"marketStatus":"休市中","change":105.06,"latestTime":"04-17 16:00:00 EDT","open":840.8,"high":858,"low":821.84,"amount":9152392304.0739,"amplitude":0.049204,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":11.71,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":102488400000,"exchange":"NYSE","adjPreClose":734.9,"dividendRate":0.006191,"preHourTrading":{"tag":"盘前","latestPrice":840.8,"preClose":734.9,"latestTime":"09:29 EDT","volume":293565,"amount":241459531.66349998,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":844,"preClose":839.96,"latestTime":"19:59 EDT","volume":140169,"amount":117746598.8407,"timestamp":1744934397934},"volumeRatio":3.1906439827178046,"impliedVol":0.4606,"impliedVolPercentile":0.8964},"requestUrl":"/m/hq/s/LLY","defaultTab":"news","newsList":[{"id":"2528107268","title":"诺和诺德、礼来“二王争霸”，国产GLP-1抢夺新适应症，恒瑞医药们不想只做减肥神药","url":"https://stock-news.laohu8.com/highlight/detail?id=2528107268","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528107268?lang=zh_cn&edition=full","pubTime":"2025-04-19 17:46","pubTimestamp":1745055988,"startTime":"0","endTime":"0","summary":"GLP-1（胰高血糖素样肽-1）类药物的适应症不只停留在糖尿病与减重领域，赛道中的玩家们正在加速向其他代谢性疾病及神经系统等更广阔的领域扩围。4月14日，药物临床试验登记与信息公示平台官网显示，信达生物（01801.HK）登记了一项评估玛仕度肽（IBI362）在患有中重度阻塞性睡眠呼吸暂停且肥胖的受试者中有效性和安全性的Ⅲ期临床试验（GLORY-OSA）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504193381946449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4533","LU0689472784.USD","LU1069344957.HKD","LU2361045086.USD","LU1988902786.USD","GLP","BK4599","SG9999014914.USD","LU1868837300.USD","SGXZ99366536.SGD","SG9999015986.USD","LU1023059063.AUD","LU1712237335.SGD","BK4585","LU1093756168.USD","LU1917777945.USD","BK4590","LU0471298777.SGD","LU2360106947.USD","LU1548497426.USD","LU2264538146.SGD","LU0466842654.USD","IE00BJT1NW94.SGD","LU1989771016.USD","LU0708995401.HKD","LU0256863811.USD","LU0471298694.HKD","LU2237438978.USD","LU2552382215.SGD","LU0079474960.USD","LU1868837136.USD","LU1057294990.SGD","BK4007","LU2468319806.SGD","LU2361044865.SGD","NVO","LU0385154629.USD","LU0198837287.USD","IE00BK4W5M84.HKD","LU0238689110.USD","LU1551013425.SGD","LU0203202063.USD","LLY","SG9999013999.USD","SGXZ57979304.SGD","IE0009355771.USD","LU0114720955.EUR","LU0943347566.SGD","LU0096364046.USD","LU2471134523.USD"],"gpt_icon":1},{"id":"2528096721","title":"减重GLP-1制剂将进入每日一次“口服”时代 礼来回应：已在准备产能计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2528096721","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528096721?lang=zh_cn&edition=full","pubTime":"2025-04-18 23:22","pubTimestamp":1744989770,"startTime":"0","endTime":"0","summary":"4月17日，礼来制药公布旗下口服GLP-1（胰高血糖素样肽-1）制剂“Orforglipron”的临床数据，在最高剂量下，每日服用一次Orforglipron的患者实现了平均减重7.3kg（7.9%）。这一表现超过了礼来之前预计的减重范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504183381594279.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504183381594279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0006306889.USD","LU1127390331.HKD","SG9999014906.USD","LU2023250504.SGD","LU0708995401.HKD","LU1868836591.USD","LU1983299246.USD","LU1974910355.USD","LU0943347566.SGD","LU1061106388.HKD","LU1720051017.SGD","BK4590","LU2471134523.USD","LU1551013342.USD","LU1623119135.USD","LU2265009873.SGD","LU0466842654.USD","BK4533","LU2211815571.USD","LU0079474960.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU0114720955.EUR","SG9999014898.SGD","LU2089984988.USD","LU1712237335.SGD","LU0471298777.SGD","SG9999014914.USD","SGXZ31699556.SGD","LLY","SGXZ81514606.USD","LU2491050071.SGD","LU1267930730.SGD","LU0882574139.USD","LU0238689110.USD","SG9999001176.USD","SGXZ51526630.SGD","LU0385154629.USD","GLP","LU0106261372.USD","LU2063271972.USD","LU2324357040.USD","LU2471134879.HKD","LU0096364046.USD","LU2491050154.USD","LU1868836914.USD","LU1064131342.USD","LU2602419157.SGD","SG9999015945.SGD","SG9999018857.SGD"],"gpt_icon":1},{"id":"1188540307","title":"礼来预计年底前向全球监管机构提交新款减肥药的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1188540307","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188540307?lang=zh_cn&edition=full","pubTime":"2025-04-18 17:42","pubTimestamp":1744969324,"startTime":"0","endTime":"0","summary":"礼来公布了3期临床研究的积极顶线结果。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY"],"gpt_icon":0},{"id":"2528599300","title":"礼来预计年底前向全球监管机构提交orforglipron用于体重管理的上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2528599300","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528599300?lang=zh_cn&edition=full","pubTime":"2025-04-18 17:40","pubTimestamp":1744969227,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1623119135.USD","LU0114720955.EUR","LU0320765059.SGD","LU2264538146.SGD","LU1291159041.SGD","SG9999001176.USD","LU0708995401.HKD","LU0256863902.USD","LU0094547139.USD","LU0096364046.USD","LU0238689110.USD","LU0289739699.SGD","LU1804176565.USD","LU0689472784.USD","LU2361044949.HKD","LU0122379950.USD","IE00B4R5TH58.HKD","LU2750360641.GBP","BK4588","LU2471134879.HKD","SG9999015978.USD","SG9999014898.SGD","LU1093756168.USD","LU0097036916.USD","BK4581","LU2602419157.SGD","IE0009355771.USD","LU0006306889.USD","LU0354030511.USD","LU1093756325.SGD","LU0820561909.HKD","LU1720051017.SGD","LU1232071149.USD","SG9999018857.SGD","LLY","BK4590","LU1548497426.USD","LU0672654240.SGD","LU0058720904.USD","LU1057294990.SGD","LU0203201768.USD","IE00B1BXHZ80.USD","LU1989771016.USD","SGXZ51526630.SGD","GLP","LU0109391861.USD","SG9999001176.SGD","LU1720051108.HKD","BK4534","LU0466842654.USD"],"gpt_icon":0},{"id":"2528059212","title":"礼来公布口服降糖药积极结果，或年底前提交用于体重管理上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2528059212","media":"澎湃新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528059212?lang=zh_cn&edition=full","pubTime":"2025-04-18 17:20","pubTimestamp":1744968000,"startTime":"0","endTime":"0","summary":"“GLP-1双雄”之一的礼来公布口服小分子GLP-1药物orforglipron在糖尿病领域的积极研究结果，也让行业对口服小分子减肥药充满期待。当地时间4月17日，礼来公布3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了orforglipron对比安慰剂，在饮食控制和运动基础上血糖控制仍不佳的2型糖尿病患者中的安全性和有效性。礼来预计将在今年年底前向全球监管机构提交orforglipron用于体重管理的上市申请，预计于2026年提交其用于治疗2型糖尿病的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041817225394d9e907&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041817225394d9e907&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1868837136.USD","LU1551013425.SGD","LU2023250504.SGD","LU0096364046.USD","LU1548497426.USD","LU2552382132.HKD","LU2491050071.SGD","LU0106261372.USD","IE00BJJMRZ35.SGD","SG9999015986.USD","LU0114720955.EUR","SGXZ51526630.SGD","LU1974910355.USD","LU0354030438.USD","IE0004445239.USD","LU1804176565.USD","LU1868836757.USD","LU2750360641.GBP","SGXZ57979304.SGD","LU2324357040.USD","LU0823416689.USD","LU0203202063.USD","LU1551013342.USD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU1988902786.USD","LU0256863811.USD","LLY","LU1061106388.HKD","SGXZ81514606.USD","LU2264538146.SGD","LU0820561818.USD","LU2361044865.SGD","IE0009355771.USD","LU1868836591.USD","LU2237438978.USD","IE00BK4W5L77.USD","LU0689472784.USD","LU1291159041.SGD","LU2360106947.USD","LU0203201768.USD","BK4533","LU1057294990.SGD","LU0256863902.USD","LU0882574055.USD","LU1280957306.USD","IE00B4R5TH58.HKD","LU1035775433.USD","LU0079474960.USD","LU2361045086.USD"],"gpt_icon":1},{"id":"2528310650","title":"大摩：口服减肥药Orforglipron成股价推动力 礼来还能再涨34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528310650","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528310650?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:54","pubTimestamp":1744962872,"startTime":"0","endTime":"0","summary":"礼来最近公布，其口服减肥药Orforglipron在三期临床试验中表现出色，该药物在减肥效果上可以媲美甚至超越注射型GLP-1药物，摩根士丹利将这一消息视为礼来股票的积极催化剂。试验结果显示，服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。试验结果还显示，Orforglipron整体安全性和已上市GLP-1类药物一致，主要不良反应为腹泻、恶心等胃肠道反应，未观察到肝安全性风险信号。市场前景方面，摩根士丹利预计Orforglipron 2033年销售额将达到约70亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418160308973c512f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"17136e9096e01d550821b3b9313a36c7","theme_name":"🔥热榜No.9 · 礼来药片在后期试验中使体重减轻了7.9%","theme_type":2,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418160308973c512f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2237443465.HKD","SGXZ31699556.SGD","LU2271345857.HKD","LU2750360641.GBP","IE00BK4W5M84.HKD","LU0456855351.SGD","IE00B4R5TH58.HKD","IE00BJLML261.HKD","IE00BK4W5L77.USD","LLY","BK4127","LU0158827781.USD","LU2750360997.AUD","LU0096364046.USD","LU2471134796.USD","LU0882574055.USD","LU0354030438.USD","IE0009355771.USD","LU0795875086.SGD","SG9999001176.SGD","LU2468319806.SGD","LU1093756168.USD","IE00BKVL7J92.USD","LU1804176565.USD","LU0098860793.USD","LU0114720955.EUR","LU2361045086.USD","LU2471134952.CNY","BK4007","LU2361044949.HKD","IE00B2B36J28.USD","LU2324357040.USD","BK4516","LU0385154629.USD","LU2361044865.SGD","LU0320765646.SGD","LU1983299246.USD","BK4581","LU2471134879.HKD","SG9999013999.USD","SG9999015978.USD","LU2471134523.USD","SG9999001176.USD","LU0354030511.USD","LU1720051108.HKD","LU2237443895.HKD","SGXZ81514606.USD","LU2491049909.HKD","LU2360106947.USD","LU1988902786.USD"],"gpt_icon":1},{"id":"2528398720","title":"GLP-1减肥药市场博弈：礼来领航突破、辉瑞折戟沉沙，创新战如何取胜？","url":"https://stock-news.laohu8.com/highlight/detail?id=2528398720","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528398720?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:37","pubTimestamp":1744961820,"startTime":"0","endTime":"0","summary":"全球GLP-1减肥药市场正迎来新一轮格局重塑。礼来在GLP-1赛道实现突破性进展之际，辉瑞却因安全性问题终止了口服GLP-1药物Danuglipron的研发，这也标志着其在该赛道的再次失利。在安全性方面，ACHIEVE-1研究中，orforglipron的整体安全性与GLP-1类药物一致。在礼来有效性、安全性均获得较好反响的同时，辉瑞安全性问题致口服赛道折戟。这是辉瑞在GLP-1减重药上的再次折戟。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041815395094d9c96c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041815395094d9c96c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BLSP4239.USD","LU1917777945.USD","LLY","LU2357305700.SGD","LU0122379950.USD","LU2106854487.HKD","BK4581","LU0820561818.USD","LU2471134879.HKD","LU1127390331.HKD","LU1894683264.USD","BK4516","IE00B1BXHZ80.USD","LU0708995401.HKD","LU0109391861.USD","IE00BJJMRZ35.SGD","LU2264538146.SGD","SGXZ99366536.SGD","LU2237443622.USD","SGXZ51526630.SGD","BK4599","LU0943347566.SGD","LU1551013425.SGD","LU1868836757.USD","SG9999013999.USD","LU0203201768.USD","LU0238689110.USD","LU1868836914.USD","LU1057294990.SGD","LU2360106947.USD","SG9999017495.SGD","BK4588","LU1720051108.HKD","SG9999015945.SGD","BK4533","GLP","PFE","LU0321505439.SGD","LU0234572021.USD","BK4007","LU1061106388.HKD","LU2750360641.GBP","SG9999015986.USD","LU1974910355.USD","LU1983299246.USD","LU0417517546.SGD","LU1988902786.USD","IE00BK4W5L77.USD","SGXZ31699556.SGD","LU2237443895.HKD"],"gpt_icon":1},{"id":"2528080431","title":"礼来首个小分子口服GLP-1药物3期临床研究成功 有望颠覆减重药物格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080431","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528080431?lang=zh_cn&edition=full","pubTime":"2025-04-18 14:07","pubTimestamp":1744956431,"startTime":"0","endTime":"0","summary":"本报讯（记者李春莲见习记者梁傲男）4月17日，全球制药巨头礼来公司公布了3期临床研究ACHIEVE-1的积极顶线结果，该研究评估了Orforglipron与安慰剂相比，在患有2型糖尿病和仅通过饮食和运动控制不足的成人中的安全性和有效性。4月17日，礼来股价收涨超14%，创下自2023年8月份以来的最大单日涨幅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504183381169424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0471298694.HKD","LU1093756168.USD","LU2357305700.SGD","LU0114720955.EUR","LU1280957306.USD","IE0004445239.USD","SG9999014898.SGD","LU2211815571.USD","IE00BK4W5M84.HKD","LU0203202063.USD","LU0079474960.USD","IE00BK4W5L77.USD","LU0417517546.SGD","LU2237443465.HKD","LU0289739699.SGD","LU1983299246.USD","LU2468319806.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0385154629.USD","IE00B2B36J28.USD","IE00BJLML261.HKD","LU0094547139.USD","BK4581","LU0820561818.USD","LU0061475181.USD","LU1988902786.USD","SG9999013999.USD","LU1232071149.USD","SG9999014880.SGD","LU1814569148.SGD","LLY","LU1720051108.HKD","LU1366192091.USD","LU2237438978.USD","LU0006306889.USD","SG9999015945.SGD","LU2552382132.HKD","LU0689472784.USD","SG9999018865.SGD","LU1127390331.HKD","LU2237443549.SGD","BK4533","SGXZ31699556.SGD","LU2471134523.USD","LU1064131342.USD","GLP","SG9999017495.SGD","IE0009355771.USD","LU0882574055.USD"],"gpt_icon":1},{"id":"2528076427","title":"礼来4月17日成交额为91.53亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528076427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528076427?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:53","pubTimestamp":1744941197,"startTime":"0","endTime":"0","summary":"美东时间2025年4月17日，礼来成交额为91.53亿美元，成交额较昨日增加275.58%，当日成交量为1085.34万股。礼来于2025年4月17日涨14.3%，报839.96美元，该股过去5个交易日涨16.51%，年初至今涨8.99%，过去60日涨11.59%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-17|91.53亿|275.58%|1085.34万|#|2025-04-16|24.37亿|30.87%|330.26万|#|2025-04-15|18.62亿|-28.31%|245.81万|#|2025-04-14|25.98亿|-0.95%|346.12万|#|2025-04-11|26.23亿|-12.56%|360.34万|礼来制药公司是一家专注于神经科学、心脏代谢、癌症和免疫学的制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418095319a6beaf60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418095319a6beaf60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0640476718.USD","LU0289739699.SGD","LU1035775433.USD","LU1093756325.SGD","LU2089984988.USD","LU2211815571.USD","LU2602419157.SGD","LLY","LU0354030511.USD","LU2750360641.GBP","LU1868836757.USD","LU0456855351.SGD","LU2750360997.AUD","LU2471134879.HKD","LU1804176565.USD","LU0354030438.USD","SG9999015978.USD","IE00BK4W5L77.USD","LU1291159041.SGD","LU2265009873.SGD","LU1989771016.USD","LU1868836591.USD","IE0004445239.USD","LU0882574139.USD","LU0256863902.USD","IE0009355771.USD","SG9999001176.SGD","LU1232071149.USD","LU2491050154.USD","LU0820561818.USD","LU2237443382.USD","LU1061106388.HKD","LU0672654240.SGD","LU2237443895.HKD","LU0471298777.SGD","BK4534","SG9999014914.USD","BK4588","LU0943347566.SGD","LU1093756168.USD","LU0079474960.USD","LU2552382132.HKD","LU0689472784.USD","SG9999015986.USD","LU1983299246.USD","LU2264538146.SGD","LU1551013425.SGD","LU2106854487.HKD","LU2491050071.SGD","LU2461242641.AUD"],"gpt_icon":1},{"id":"1170316139","title":"“减肥神药”进入口服时代，礼来登顶“减肥药王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1170316139","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170316139?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:36","pubTimestamp":1744940179,"startTime":"0","endTime":"0","summary":"数据显示，服用Orforglipron的参与者在40周后平均减轻了16磅，约占体重的7.9%，这一表现超过了礼来之前预计的4%至7%减重范围。华尔街分析师普遍认为，GLP-1减肥药领域正在从注射剂型向便捷的口服形式转变，而礼来已经取得了早期领先优势。登顶减肥药之王？报道称，辉瑞的退出进一步巩固了礼来在这一领域的领先地位。根据临床试验数据库，礼来公司的主要肥胖症试验最早将于7月完成。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3745456","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3745456","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减肥神药”进入口服时代，礼来登顶“减肥药王”？","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_api","symbols":["LU0198837287.USD","LU0256863811.USD","LU0823416689.USD","LU0708995401.HKD","LLY","LU0882574139.USD","LU0385154629.USD","IE0004445239.USD","LU0289739699.SGD","LU0061475181.USD","IE00BJJMRZ35.SGD","BK4516","LU0456855351.SGD","IE00B4R5TH58.HKD","LU0820561818.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0943347566.SGD","BK4581"],"gpt_icon":0},{"id":"2528778014","title":"美股收盘：三大股指涨跌不一 礼来大涨14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528778014","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528778014?lang=zh_cn&edition=full","pubTime":"2025-04-18 04:01","pubTimestamp":1744920067,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["09988","DXD","BABA","USAW.SI","NVDU","SOHU","UDOW","SDOW","OEX","03086","MACW.SI","TQQQ","AAPL","EVS.SI","NVDS.UK","SH","SNVD.UK","000008.SH","OEF","SPY","DJX","QQQ",".DJI","ESmain","YMmain","NVDA","NVDS","NVD","SPXU","PSQ","NVIW.SI","LLY","XPEV","NVDX","ARTL","TSYW.SI",".SPX","QID","159632","2NVD.UK","USJW.SI","HXC","NQmain","09868","NVDD","NVDY","NDX","MNQmain",".IXIC","DDM"],"gpt_icon":0},{"id":"2528080941","title":"太平洋医药日报：礼来口服GLP-1受体激动剂ORFORGLIPRON三期临床成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2528080941","media":"太平洋证券股份...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528080941?lang=zh_cn&edition=full","pubTime":"2025-04-18 00:00","pubTimestamp":1744905600,"startTime":"0","endTime":"0","summary":"行业要闻：4 月17 日，礼来宣布，公司口服GLP-1受体激动剂Orforglipron 奥格列龙在一项关键的III 期临床试验中取得了具有统计学意义的积极结果。这项研究评估了Orforglipron 与安慰剂相比，在仅通过饮食和运动控制血糖不佳的成人2 型糖尿病患者中的安全性和有效性。Orforglipron 是一种研究性的、每日一次口服的小分子（非肽）胰高血糖素样肽-1 受体激动剂，可在一天中的任何时间服用，且不受食物和饮水限制。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041814031994d9b2b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"17136e9096e01d550821b3b9313a36c7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041814031994d9b2b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2211815571.USD","LU2237438978.USD","BK4590","LU0238689110.USD","LU0354030438.USD","LU1023059063.AUD","SG9999014914.USD","LU0203201768.USD","BK4581","LU2237443382.USD","LU1868836591.USD","LU2471134796.USD","LU1093756325.SGD","LU2063271972.USD","LU1917777945.USD","IE0002141913.USD","LU1720051108.HKD","LU1057294990.SGD","LU0256863902.USD","IE00BK4W5M84.HKD","LU2491050154.USD","LLY","LU2112291526.USD","LU2468319806.SGD","LU0320765059.SGD","LU0882574139.USD","LU2237443549.SGD","LU0466842654.USD","LU1232071149.USD","LU2361044949.HKD","LU1989771016.USD","LU1291159041.SGD","LU2602419157.SGD","LU1868836757.USD","SG9999015952.SGD","LU2237443465.HKD","SG9999001176.USD","LU1868837136.USD","SGXZ57979304.SGD","LU1974910355.USD","GLP","SGXZ99366536.SGD","SG9999015945.SGD","LU2106854487.HKD","LU2360106947.USD","SG9999001176.SGD","LU2750360997.AUD","BK4007","LU0708995401.HKD","BK4516"],"gpt_icon":1},{"id":"2528575741","title":"美股异动 | 口服减肥药Orforglipron三期临床数据亮眼 礼来(LLY.US)涨逾13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528575741","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528575741?lang=zh_cn&edition=full","pubTime":"2025-04-17 22:37","pubTimestamp":1744900651,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，礼来(LLY.US)涨逾13%，报833.45美元。消息面上，礼来口服减肥药Orforglipron在三期临床试验中表现出色，有望成为无需注射的减肥药替代品。试验结果显示，礼来的Orforglipron在减肥效果上可以媲美甚至超越注射型GLP-1药物。服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。此外，这款口服药还平均降低了血糖水平1.3%，而Ozempic降低了2.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0122379950.USD","LU1232071149.USD","LLY","LU2361044865.SGD","IE00B1BXHZ80.USD","LU0471298694.HKD","LU0466842654.USD","LU2264538146.SGD","LU2491049909.HKD","LU1267930730.SGD","LU2237443549.SGD","SG9999015978.USD","LU1988902786.USD","LU0672654240.SGD","LU1023059063.AUD","LU2237438978.USD","BK4581","SGXZ57979304.SGD","LU0203202063.USD","LU1868836757.USD","SGXZ81514606.USD","SGXZ99366536.SGD","BK4533","LU2237443978.SGD","LU0238689110.USD","SG9999001176.SGD","LU0097036916.USD","LU1061106388.HKD","SG9999018857.SGD","IE00BJLML261.HKD","LU0006306889.USD","LU2471134523.USD","LU0354030511.USD","LU0471298777.SGD","LU1814569148.SGD","LU2552382132.HKD","LU0058720904.USD","IE00BJT1NW94.SGD","LU0943347566.SGD","LU2471134796.USD","LU2750360997.AUD","LU0708995401.HKD","LU2112291526.USD","LU2471134952.CNY","SG9999014880.SGD","LU0256863902.USD","LU2237443382.USD","LU2491050154.USD","LU0203201768.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2528743174","title":"礼来(LLY)涨超16% 诺和诺德(NVO)跌逾8% Orforglipron研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2528743174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528743174?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:45","pubTimestamp":1744897552,"startTime":"0","endTime":"0","summary":"与此同时，诺和诺德股价走低，跌8.45%，报57.56美元。消息面上，公司宣布III期ACHIEVE-1研究取得积极结果，该研究评估了orforglipron与安慰剂相比在饮食和运动单独控制不佳的2型糖尿病成人中的安全性和疗效。Orforglipron是首个成功完成III期研究的口服小分子胰高血糖素样肽-1受体激动剂，服用时无需食物和水限制。Orforglipron在后期试验中，最高剂量下可使 2 型糖尿病患者体重减轻16.0 磅，并降低血糖。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/M2RkMDMzZDc5MTczNjIzNzY2ODA2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/M2RkMDMzZDc5MTczNjIzNzY2ODA2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134952.CNY","IE0002141913.USD","LU0097036916.USD","LU0708995401.HKD","BK4532","IE00BK4W5M84.HKD","LU0672654240.SGD","SGXZ57979304.SGD","LU0238689110.USD","LLY","LU1057294990.SGD","IE0009355771.USD","LU1623119135.USD","IE00B1BXHZ80.USD","LU0354030511.USD","LU0823416689.USD","LU1093756325.SGD","LU0256863902.USD","NVO","IE0004445239.USD","LU0385154629.USD","LU0354030438.USD","LU1232071149.USD","LU0689472784.USD","SG9999015952.SGD","SGXZ31699556.SGD","BK4585","LU1280957306.USD","LU1720051017.SGD","LU2357305700.SGD","LU2552382132.HKD","SGXZ51526630.SGD","LU0882574139.USD","SG9999018857.SGD","LU1093756168.USD","SG9999014880.SGD","LU2750360997.AUD","LU0058720904.USD","LU2360106947.USD","LU2552382215.SGD","SG9999014914.USD","LU2471134523.USD","LU0198837287.USD","LU2237438978.USD","LU2237443978.SGD","LU1989771016.USD","LU2491049909.HKD","BK4516","LU1868837300.USD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2528719246","title":"美股异动 | 礼来涨超16%，口服减肥药Orforglipron三期临床数据亮眼，效果超越诺和诺德Ozempic","url":"https://stock-news.laohu8.com/highlight/detail?id=2528719246","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528719246?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:40","pubTimestamp":1744897237,"startTime":"0","endTime":"0","summary":"服用礼来Orforglipron的患者平均减轻16磅，相当于体重的7.9%。相比之下，诺和诺德的明星产品Ozempic在最高剂量下糖尿病患者仅减轻约6%的体重。礼来股价在美股盘前交易中飙升14%，而诺和诺德欧股跌近6.8%。","market":"hk","thumbnail":"https://static.tigerbbs.com/54b138fe6c8c9fd6dabf7feab262ebb6","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/54b138fe6c8c9fd6dabf7feab262ebb6"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3745424","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3745424","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LLY"],"gpt_icon":1},{"id":"1166346461","title":"异动解读 | 礼来口服减肥新药临床成功，股价盘中暴涨14.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166346461","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166346461?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:35","pubTimestamp":1744896911,"startTime":"0","endTime":"0","summary":"礼来公司股价今日盘中大涨14.25%，引发市场广泛关注。这一显著涨幅源于公司宣布其口服减肥药Orforglipron在3期临床试验中取得积极成果。礼来公司表示，对于在全球推出Orforglipron而不受供应限制的能力充满信心。分析师普遍看好礼来的发展前景，认为该公司在快速增长的减肥药市场中占据有利地位。随着肥胖症和相关健康问题的日益普遍，市场对有效且便捷的减肥解决方案的需求持续增长，这可能为礼来带来可观的收入增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LLY"],"gpt_icon":0},{"id":"1183920182","title":"开盘 | 美股三大指数涨跌不一！礼来涨超14%， 联合健康跌超17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183920182","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183920182?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:30","pubTimestamp":1744896636,"startTime":"0","endTime":"0","summary":"4月17日，美股开盘涨跌不一，道指跌1.23%，纳指涨0.54%，标普500指数涨0.39%。台积电涨近3%，Q1净利润同比增长60.3%，发布乐观业绩指引。 礼来涨超14%，口服减肥药3期试验取得积极成果。 联合健康跌超17%，下调全年盈利指引。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFSS8Q28.SGD","LU0466842654.USD","IE00B1BXHZ80.USD","IE00BK4W5M84.HKD","IE0002270589.USD","LU0096364046.USD","LU0106261372.USD","IE00B19Z8X17.USD","IE000M9KFDE8.USD","BK4581",".DJI","LLY",".IXIC","UNH","LU0689472784.USD","LU0097036916.USD","BK4516","LU0122379950.USD","IE00BKVL7J92.USD","LU1064131342.USD","LU0354030511.USD",".SPX","LU0882574055.USD"],"gpt_icon":0},{"id":"2528274865","title":"美股三大股指走势分化 礼来大涨13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528274865","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528274865?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:30","pubTimestamp":1744896633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LLY","MACW.SI","UDOW","LU2491049909.HKD","SDOW","PSQ","UPRO","SSO","TWmain","IE00B1XK9C88.USD","03086","IE00BJJMRZ35.SGD","OEF","DXD","TSM","SDS","USAW.SI","QID","LU0541502299.USD","159659","YMmain","03145","SPY","DOG","LU0823434583.USD","ESmain","LU0265550946.USD","TQQQ","TSYW.SI","BK4561","DDM",".SPX","OEX","DJX",".DJI","EWT","NVIW.SI","IVV","SPXU","AAPL","IE00BSNM7G36.USD","SQQQ","MNQmain",".IXIC","QLD","NQmain","USJW.SI","SH","LU0077335932.USD","QQQ"],"gpt_icon":0},{"id":"2528488277","title":"礼来(LLY)研发的药物帮助糖尿病患者减轻近8%的体重","url":"https://stock-news.laohu8.com/highlight/detail?id=2528488277","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528488277?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:23","pubTimestamp":1744896202,"startTime":"0","endTime":"0","summary":"金吾财讯 | 礼来(LLY)公布实验性减肥药临床试验结果。公司测试奥格利普龙（Orforglipron）的药物在糖尿病、肥胖症以及睡眠呼吸暂停等相关疾病中的作用，实验性药物Orforglipron在后期试验中，最高剂量下可使 2 型糖尿病患者体重减轻16.0 磅（7.9%），并降低血糖。礼来公司表示，研究结束时患者尚未达到体重平台期，这表明患者减重幅度可能更大。投资者和分析师此前预计，该药物的疗效至少会与诺和诺德公司（Novo Nordisk）旗下的重磅糖尿病药物奥泽匹克（Ozempic）一样好。","market":"us","thumbnail":"https://static.szfiu.com/news/20210625/ZTg0OWM0M2E2YjcwZGM0MTQ1YzIxNjI0NjAwNDk2ODM0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/ZTg0OWM0M2E2YjcwZGM0MTQ1YzIxNjI0NjAwNDk2ODM0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","SG9999001176.SGD","LU0058720904.USD","BK4516","LU1868837136.USD","LU2112291526.USD","LU0106261372.USD","BK4007","IE00B1BXHZ80.USD","LU2552382058.USD","LU2211815571.USD","LU0882574139.USD","LU0256863811.USD","SGXZ81514606.USD","SG9999015978.USD","LU0672654240.SGD","LU1291159041.SGD","LU1868836757.USD","SG9999001176.USD","LU2552382132.HKD","BK4585","LU2491049909.HKD","IE00B4R5TH58.HKD","LU0689472784.USD","LU1720051108.HKD","LU0823416689.USD","SGXZ99366536.SGD","LU1061106388.HKD","LU0256863902.USD","LU2471134879.HKD","SG9999015986.USD","SGXZ57979304.SGD","LU0096364046.USD","LU0471298694.HKD","LU2237443622.USD","SG9999015945.SGD","LU1868837300.USD","LU1712237335.SGD","LU1064131342.USD","LU1127390331.HKD","LU1551013425.SGD","SG9999017495.SGD","LU0094547139.USD","LU2602419157.SGD","IE00BJLML261.HKD","LU0882574055.USD","LU2237443549.SGD","LU1232071149.USD","LU1988902786.USD","LLY"],"gpt_icon":0},{"id":"2528171056","title":"金十数据整理：每日美股市场要闻速递（4月17日，周四）","url":"https://stock-news.laohu8.com/highlight/detail?id=2528171056","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2528171056?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:17","pubTimestamp":1744895835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVDS.UK","NVDX","NVDA","NVDU","LU0128525689.USD","LLY","NVDL","IE00BYXW3230.USD","TNmain","SNVD.UK","LU2506951792.HKD","NVD","ZNmain","LU2413666426.HKD","LU2417539215.USD","LU2471134879.HKD","UNH","LU0444973449.USD","LU0061474960.USD","NVIW.SI","3NVD.UK","ZTmain","LU1861127337.USD","ZFmain","IE0004445239.USD","NVD3.UK","NVDS","TSM","LU0130102774.USD","AXP","LU0203201768.USD","EWT","HK0000934320.USD","TSLA","NVD2.UK","NVDD","03145","LU0943347566.SGD","IE00B19Z9Z06.USD","TSLL","TWmain","YINN","LU1721428933.USD","TSYW.SI","ZBmain","IE00B19Z9505.USD","UBmain","2NVD.UK","LU0868494708.USD","NVDY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lilly.com","stockEarnings":[{"period":"1week","weight":0.1651},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1574},{"period":"6month","weight":-0.085},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.088}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"礼来公司于1901年在印第安纳州注册成立，其前身是1876年由伊利·礼来上校在印第安纳州印第安纳波利斯创立的药品生产企业。公司发现，开发，制造和销售重要医药产品。公司的宗旨是将“关爱”与“发现”结合起来，为世界各地的人们创造更美好的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.511111,"avgChangeRate":0.012368},{"month":2,"riseRate":0.511111,"avgChangeRate":0.000157},{"month":3,"riseRate":0.6,"avgChangeRate":0.012761},{"month":4,"riseRate":0.565217,"avgChangeRate":0.018681},{"month":5,"riseRate":0.422222,"avgChangeRate":0.014916},{"month":6,"riseRate":0.6,"avgChangeRate":0.02296},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.000346},{"month":8,"riseRate":0.422222,"avgChangeRate":0.004313},{"month":9,"riseRate":0.444444,"avgChangeRate":0.001418},{"month":10,"riseRate":0.577778,"avgChangeRate":0.012708},{"month":11,"riseRate":0.733333,"avgChangeRate":0.026326},{"month":12,"riseRate":0.577778,"avgChangeRate":0.030474}],"exchange":"NYSE","name":"礼来","nameEN":"Eli Lilly"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼来,LLY,礼来股票,礼来股票老虎,礼来股票老虎国际,礼来行情,礼来股票行情,礼来股价,礼来股市,礼来股票价格,礼来股票交易,礼来股票购买,礼来股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼来(LLY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼来(LLY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}